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Introduction
Despite the fact that the current standard 
tuberculosis (TB) treatment, which is given to more 
than 8 million people each year, is a product of the 
best scientific advance of the 1960s, little is known 
about the mechanism of hepatotoxicity, one of 
the most serious adverse effects of TB treatment. 
Hepatotoxicity can be fatal when not recognized in 
time. Between 2 and 28% of TB patients develop hepa-
totoxicity during TB treatment. Adverse effects have 
a negative impact on therapy adherence and may, 
therefore, have serious consequences for treatment 
success rates, relapse, and the emergence of drug 
resistance (Tostmann et al., 2008).
Recent studies suggest that pyrazinamide causes 
more hepatotoxicity than previously perceived 
(Chang et al., 2008; Yee et al., 2003). Further, the high 
rates of hepatotoxicity observed in pyrazinamide-
containing prophylactic regimens for treatment of 
latent TB have reassessed the hepatotoxic potential of 
this drug (Jasmer and Daley, 2003; Younossian et al., 
2005). Despite the important role of pyrazinamide in 
TB treatment, little is known about the mechanism 
of pyrazinamide-induced hepatotoxicity. Reactive 
metabolites, rather than the parent drug itself, are 
suggested to be responsible for most idiosyncratic 
drug reactions (Knowles et al., 2000). Pyrazinamide 
may exhibit both dose-dependent and idiosyncratic 
hepatoxicity (Chang et al., 2008).
Pyrazinamide (pyrazinoic acid amide) is converted 
to pyrazinoic acid by hepatic microsomal deamidase 
and is further hydroxylated to 5-hydroxy-pyrazinoic 
acid by xanthine oxidase (see Figure 1). A parallel 
metabolic pathway is the direct oxidation of pyrazi-
namide to 5-hydroxy-pyrazinamide by xanthine oxi-
dase, which can be converted to 5-hydroxy-pyrazinoic 
acid by pyrazinamide deamidase. The metabolites are 
excreted in the urine, as is about 4% of the unchanged 
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pyrazinamide (Lacroix et al., 1989; Weiner and Tinker, 
1972).
Allopurinol is a well-known xanthine-oxidase 
inhibitor. A study showing the interaction between 
allopurinol and pyrazinamide revealed that allopuri-
nol increased the plasma concentrations of pyrazinoic 
acid and decreased those of 5-hydroxy-pyrazinoic acid 
and 5-hydroxy-pyrazinamide (Lacroix et al., 1989).
More knowledge on the mechanism of pyrazina-
mide-induced hepatotoxicity could be helpful in the 
search for hepatoprotective compounds. Whether 
pyrazinamide-induced hepatotoxicity is caused 
by pyrazinamide itself, pyrazinoic acid, or hydroxy 
metabolites could be studied by the selective inhibi-
tion of the metabolic pathways. We investigated the 
effect of xanthine-oxidase inhibition by allopurinol on 
in vitro pyrazinamide toxicity.
Methods
Cell culture
Human HepG2 hepatocellular carcinoma cells were 
grown in serum-free PC-1 medium (Cambrex, Verviers, 
Belgium), supplemented with 2 mM of L-glutamine at 
37°C in a humidified atmosphere with 5% CO
2
. The 
medium was renewed every 3 days, and when conflu-
ence was reached, cells were harvested with EDTA/
trypsin (Cambrex), washed with phosphate-buffered 
saline (PBS), and used for cytotoxicity assays.
Effect of xanthine-oxidase inhibition on in vitro 
pyrazinamide toxicity
The effect of allopurinol (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) on in vitro pyrazinamide toxicity was 
determined by the WST-1 cytotoxicity assay (Roche 
Diagnostics GmbH, Penzberg, Germany). HepG2 cells 
were seeded in flat-bottomed 96-well microtiterplates 
(Costar, Corning Inc., Corning, New York, USA) at 
60,000 cells/well and cultured for 24 hours. On day 2, 
the cells were exposed to a nontoxic concentration of 
0.1 mM of allopurinol (for xanthine-oxidase inhibi-
tion) (Lee et al., 2000) or culture medium only (control 
cells) for 24 hours. On day 3, the cells were exposed 
to six increasing concentrations of pyrazinamide for 
24 hours. At day 4, drug toxicity was assessed by the 
WST-1 assay, according to the supplier’s instructions. 
This assay is based on the reduction of the tetrazolium 
salt, WST-1, into a colored, water-soluble formazan salt 
by viable cells only. The experiment was performed in 
triplicate and was repeated five times.
Statistical analyses
We calculated the area under the curve (AUC) of 
pyrazinamide-dependent cell survival to determine 
the effect of xanthine-oxidase inhibition on pyrazi-
namide toxicity. Changes in the AUC were compared 
by using the Wilcoxon signed ranks test. Statistical 
analyses were done by using SPSS for Windows (ver-
sion 16.0; SPSS, Inc., Chicago, Illinois, USA). A P-value 
<0.05 was considered statistically significant.
Results
Pretreatment with 0.1 mM of allopurinol significantly 
decreased the area under the pyrazinamide concen-
tration–cell survival by 13% (95% confidence interval; 
2–24%; P = 0.04). This means that  xanthine-oxidase 
inhibition increased the in vitro pyrazinamide 
toxicity. Figure 2 shows the HepG2 cell survival at 
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Figure 1. Metabolism of pyrazinamide (Liacroix et al., 1989).
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different pyrazinamide concentrations with and with-
out  allopurinol pretreatment.
Discussion
A study in human volunteers showed that 
 xanthine-oxidase inhibition by allopurinol resulted 
in increased levels of pyrazinoic acid (mean AUC 
increased by 73%) and decreased levels of 5- hydroxy-
pyrazinamide (mean AUC decreased by 34%) and 
5-hydroxy-pyrazinoic acid (below detection level) 
(Lacroix et al., 1988). Considering these shifts in 
metabolic routes upon allopurinol administra-
tion, our finding that xanthine-oxidase inhibition 
increased the in vitro pyrazinamide toxicity sug-
gests two things. First, it is unlikely that the hydroxy 
metabolites are solely responsible for pyrazinamide-
induced hepatotoxicity, because if they were, in vitro 
pyrazinamide toxicity should have decreased by xan-
thine-oxidase inhibition and not increased. Second, 
pyrazinoic acid and, possibly, also pyrazinamide are 
at least partially responsible for pyrazinamide toxic-
ity, since pyrazinoic-acid concentrations are prob-
ably increased by allopurinol pretreatment.
Arthralgia is another common adverse effect of 
pyrazinamide. This arthralgia is caused by the inhi-
bition of the renal tubular secretion of uric acid by 
pyrazinoic acid that results in hyperuricemia (Lacroix 
et al., 1988). The study of Lacroix et al. showed that 
allopurinol causes a slight decrease in urate renal 
clearance due to pyrazinoic-acid accumulation, 
which is counterbalancing the hypouricemic effect 
of allopurinol. Therefore, allopurinol is ineffective for 
treating pyrazinamide-induced arthalgia (Horsfall 
et al., 1979; Lacroix et al., 1988). The finding that 
allopurinol may increase the risk on hepatotoxicity 
is another reason not to use allopurinol as treatment 
of pyrazinamide-induced arthalgia.
Results of in vitro studies may not be directly trans-
lated into in vivo toxicity. However, allopurinol inhibits 
xanthine oxidase in HepG2 cells, and it is likely that 
in vitro xanthine-oxidase inhibition causes similar 
shifts in in vitro pyrazinamide metabolism, as seen in 
humans (Lee et al., 2000; Roy et al., 1995).
Conclusions
In conclusion, we observed that inhibition of xanthine 
oxidase by a nontoxic concentration of allopurinol 
increases in vitro pyrazinamide toxicity in HepG2 cells. 
This suggests that the hydroxy metabolites of pyrazi-
namide are probably not fully responsible for pyrazi-
namide-induced toxicity, and that pyrazinoic acid and 
pyrazinamide are involved in pyrazinamide toxicity.
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